Breaking News, Collaborations & Alliances

GenomeFrontier, BioCina Partner on DNA for CAR-T Cell Therapy

Project involves development of innovative virus-free chimeric antigen receptor T cell products (CAR-T) for cancer treatment.

BioCina Pty Ltd., a global biologics contract development and manufacturing organization (CDMO), formed a new partnership with GenomeFrontier Therapeutics AU Pty Ltd., the Australian entity of GenomeFrontier Therapeutics Inc. headquartered in Taiwan, for a project involving development of innovative virus-free chimeric antigen receptor T cell products (CAR-T) for cancer treatment. BioCina will support GenomeFrontier with process development and GMP manufacturing for Minicircle DNA and Plasmid...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters